Advertisement
Australia markets closed

  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     

  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     

  • AUD/USD

    0.6618
    -0.0020 (-0.30%)
     

  • OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD

    2,348.40
    +30.40 (+1.31%)
     

  • Bitcoin AUD

    100,020.82
    -152.97 (-0.15%)
     

  • CMC Crypto 200

    1,371.48
    -46.40 (-3.27%)
     

  • AUD/EUR

    0.6178
    +0.0005 (+0.09%)
     

  • AUD/NZD

    1.0765
    +0.0012 (+0.12%)
     

  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     

  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Monthly Active Consumers: 7 compared to the 7 average estimate based on three analysts.

  • Subscribers: 778 versus the two-analyst average estimate of 866.

  • Revenue- Prescription transactions: $145.40 million compared to the $145.51 million average estimate based on five analysts. The reported number represents a change of +7.8% year over year.

  • Revenue- Other: $5.38 million versus $4.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change.

  • Revenue- Pharma Manufacturer Solutions: $24.51 million versus $23.21 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +20.1% change.

  • Revenue- Subscription: $22.60 million versus $22.56 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.

View all Key Company Metrics for GoodRx here>>>

Shares of GoodRx have returned +8.7% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research